查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1676765

美沙拉嗪市场按产品形式、给药途径、用途、最终用户和分销管道划分 - 2025-2030 年全球预测

Mesalazine Market by Product Form, Route Of Administration, Application, End-User, Distribution Channel - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 181 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计美沙拉嗪市场价值在 2024 年将达到 17.6 亿美元，在 2025 年达到 18.5 亿美元，并以 5.15% 的复合年增长率增长，到 2030 年达到 23.8 亿美元。

主要市场统计数据
基准年 2024 年 17.6亿美元
预计 2025 年 18.5亿美元
预测年份 2030 23.8亿美元
复合年增长率（%） 5.15％

美沙拉嗪是治疗各种发炎性肠道疾病肠道疾病的基石，它继续重塑医疗保健领域的治疗模式。本执行摘要对不断发展的美沙拉嗪市场格局进行了深入分析，强调了关键成长领域、策略细分和新兴竞争考察。由于配方的进步、治疗通讯协定的转变以及对以患者为中心的护理模式的更加关注，全球美沙拉嗪市场正在经历重大转变。药物传递方法的创新和对发炎疾病的深入了解使美沙拉嗪成为各种临床环境中的主要治疗选择。

近年来，临床医生和医疗保健决策者见证了我们对美沙拉嗪作用机制和治疗结果的理解的快速进步。美沙拉嗪在缓解发炎性肠道疾病、克隆氏症和溃疡性大肠炎等慢性疾病相关症状方面发挥关键作用，凸显了持续研究和实证临床策略的重要性。产业相关人员越来越重视精准医疗方法，从而整合细分市场策略，根据特定患者的需求客製化产品配方。开发这些新兴市场不仅可以改善临床结果，还可以为市场扩张和竞争差异化带来新的机会。

本报告详细介绍了不断变化的市场格局、透过多方面細項分析得出的竞争考察、区域概况、竞争情报以及针对行业领导者的可行建议。对于决策者、投资者和策略家来说，透彻了解这些动态对于将创新的、针对患者量身定制的解决方案带到最前沿至关重要。本摘要提供了美沙拉嗪生态系统的全面观点，使相关人员能够应对当前复杂的製药环境。

美沙拉嗪市场格局的变化：创新与策略发展

在过去几年里，美沙拉嗪市场经历了变革性变化，重新定义了产业的策略方向。这些变化的核心是配方技术和给药途径的进步，显着提高了患者的依从性和治疗效果。先进的研究为新的药物输送系统铺平了道路，从而提高了生物有效性并减少了副作用。差异化治疗配方的出现使得针对特定患者群体和临床情况制定个人化治疗策略成为可能。

数位健康工具和远端医疗的快速发展进一步推动了这种动态的市场环境，这有助于发炎疾病临床管理的地理扩展和优化。增强的连接性和资料主导的决策使医疗保健提供者能够准确评估治疗结果并相应地调整给药方案。这些进步已导致相关人员的关注点发生显着转变，从一刀切的做法转向精准剂量和个人化治疗。技术的采用不仅简化了病患监测，而且还有助于识别潜在的安全问题并加快监管回应和合规调整。

此外，临床实践指南的改进和现实世界实践中证据的不断采用正在加速向更具适应性的以患者为中心的护理模式的转变。研究机构、监管机构和製药公司之间的合作努力正在帮助为安全性和有效性标准设定新的基准。这些变革的累积效应使美沙拉嗪成为必不可少的治疗方法，开创了创新的新时代，并有望提高慢性发炎疾病患者的整体照护品质。

关键细分洞察详细市场細項分析

详细了解市场区隔就会发现美沙拉嗪市场的多面性。透过考虑产品剂型、给药途径、临床应用、最终用户偏好和分销管道等变量，分析将更加丰富。例如，产品形态细分涉及对灌肠液、颗粒、直肠泡沫、栓剂、锭剂等各种形态的专门研究，每种形态在吸收率和患者依从性方面都具有独特的优势。同时，给药途径也很重要，因为要比较口服和直肠给药途径，以解释便利性、剂量准确性和区域患者偏好的差异。

透过将市场分为克隆氏症、发炎性肠道疾病肠道疾病和溃疡性大肠炎等疾病，应用细分提供了进一步的见解，每种疾病都有不同的临床挑战和治疗复杂性。对于最终用户，该报告透过将居家照护环境与医院和诊所进行对比，突出了治疗环境的差异，不仅突出了患者管理的差异，还突出了不同医疗保健基础设施的利用模式的差异。最后，透过研究医院药局、网路药局和零售药局的表现来详细评估分销管道，这些管道共同促进了美沙拉嗪产品的整体可用性和市场渗透率。

这种细分有助于详细了解市场驱动因素和障碍，使相关人员能够根据病患小组和医疗保健提供者的特定需求调整其产品开发策略。综合的见解指南投资决策和产品发布，这些决策和产品发布可以精准响应当地市场动态，确保治疗解决方案保持创新和可及性。

目录

第 1 章 简介

第二章调查方法

第三章执行摘要

第四章 市场概况

第五章 市场洞察

  • 市场动态
    • 驱动程式
      • 全球发炎性肠道疾病和溃疡性大肠炎发生率上升
      • 更重视个人化医疗和标靶治疗
      • 加强胃肠道疾病治疗政府经费投入与扶持政策
    • 限制因素
      • 製造和生产成本上升对价格造成越来越大的压力
    • 机会
      • 药物研发领域的策略合作与伙伴关係推动美沙拉嗪治疗方法的创新
      • 创新临床试验设计探索新的美沙拉嗪配方
    • 任务
      • 区域市场监管合规要求严格且多样
  • 市场区隔分析
    • 产品形式：颗粒因易于管理、剂量灵活而越来越受到青睐。
    • 应用：扩大美沙拉嗪在溃疡性大肠炎的应用
  • 波特五力分析
  • PESTEL 分析
    • 政治的
    • 经济
    • 社会
    • 技术的
    • 合法的
    • 环境

6. 美沙拉嗪市场依产品形式划分

  • 灌肠剂
  • 颗粒
  • 直肠形式
  • 栓剂
  • 药片

7. 美沙拉嗪市场依给药途径划分

  • 口服
  • 直肠

8. 美沙拉嗪市场应用

  • 克隆氏症
  • 发炎性肠道疾病
  • 溃疡性大肠炎

9. 美沙拉嗪市场（按最终用户划分）

  • 家庭护理设置
  • 医院和诊所

第 10 章 美沙拉嗪市场依通路划分

  • 医院药房
  • 网路药局
  • 零售药局

第 11 章美洲美沙拉嗪市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

12. 亚太地区美沙拉嗪市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

13. 欧洲、中东和非洲的美沙拉嗪市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十四章 竞争格局

  • 2024 年市场占有率分析
  • FPNV 定位矩阵，2024 年
  • 竞争情境分析
  • 战略分析与建议

公司列表

  • AbbVie Inc.
  • Allergan Pharmaceuticals International, Ltd.
  • Amneal Pharmaceuticals, Inc.
  • Apotex Inc.
  • Axplora Group GmbH
  • Cambrex Corporation
  • Chemi SpA
  • CordenPharma International
  • Divi's Laboratories Limited
  • Dr. Falk Pharma GmbH
  • Ethypharm SAS
  • Ferring Pharmaceuticals
  • Fresenius Kabi
  • LGM Pharma
  • Lupin limited
  • Pfizer Inc.
  • Rosemont Pharmaceuticals Ltd.
  • Salix Pharmaceuticals, Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceuticals
  • Tillotts Pharma Ltd.
  • Viatris Inc.
  • Zhejiang Hengkang Pharmaceutical Co. Ltd.
  • Zydus Pharmaceuticals, Inc.
Product Code: MRR-867BED9A9E9F

The Mesalazine Market was valued at USD 1.76 billion in 2024 and is projected to grow to USD 1.85 billion in 2025, with a CAGR of 5.15%, reaching USD 2.38 billion by 2030.

KEY MARKET STATISTICS
Base Year [2024] USD 1.76 billion
Estimated Year [2025] USD 1.85 billion
Forecast Year [2030] USD 2.38 billion
CAGR (%) 5.15%

Mesalazine, a cornerstone in the treatment of various inflammatory bowel conditions, continues to reshape therapeutic paradigms in the healthcare sector. This executive summary provides an in-depth analysis of the evolving market landscape for mesalazine, elucidating key areas of growth, strategic segmentation, and emerging competitive insights. The global mesalazine market has undergone significant transformations, driven by advances in pharmaceutical formulations, shifts in treatment protocols, and an increased focus on patient-centric care models. Innovation in drug delivery methods and a deeper understanding of inflammatory disorders have positioned mesalazine as a mainstay treatment option across various clinical settings.

In recent years, clinicians and healthcare decision-makers have witnessed rapid advancements in the understanding of underlying mechanisms of action and therapeutic outcomes related to mesalazine. Its pivotal role in mitigating symptoms associated with chronic conditions such as inflammatory bowel disease, Crohn's disease, and ulcerative colitis underscores the importance of ongoing research and evidence-based clinical strategies. Industry stakeholders are increasingly prioritizing precision medicine approaches, resulting in the integration of segmented market strategies that align product formulation with specific patient needs. These developments have not only facilitated improved clinical outcomes but also fostered novel opportunities for market expansion and competitive differentiation.

The ensuing sections delve deeper into transformative shifts within the market landscape, key insights derived from multifaceted segmentation analysis, regional distinctions, competitive intelligence, and actionable recommendations for industry leaders. It is essential for decision-makers, investors, and strategists to fully comprehend these dynamics to bring innovative, patient-tailored solutions to the forefront. This summary offers a comprehensive perspective on the mesalazine ecosystem, ensuring that stakeholders are well-equipped to navigate the complexities of the current pharmaceutical environment.

Transformative Shifts in the Mesalazine Market Landscape: Innovations and Strategic Developments

Over the past few years, the mesalazine market has experienced transformative shifts that have redefined the industry's strategic direction. Central to these transformations is the evolution in formulation technologies and administration routes, which have significantly enhanced patient adherence and treatment efficacy. Advanced research has paved the way for novel drug delivery systems, resulting in improved bioavailability and reduced adverse effects. The emergence of differentiated therapeutic formulations has allowed for personalized treatment strategies that cater to specific patient demographics and clinical scenarios.

This dynamic market environment is further propelled by the rapid evolution of digital health tools and telemedicine, which have contributed to geographical expansion and optimized clinical management of inflammatory conditions. Enhanced connectivity and data-driven decision-making have enabled healthcare providers to precisely evaluate treatment outcomes and tailor dosage regimens accordingly. These advancements have resulted in a noticeable shift in stakeholder focus-from a one-size-fits-all approach to precision dosing and individualized patient therapy. The incorporation of technology has not only streamlined patient monitoring but has also helped in the identification of potential safety concerns, expediting regulatory responses and compliance adjustments.

Additionally, refinements in clinical practice guidelines and the increasing adoption of real-world evidence are accelerating the transition toward more adaptive, patient-centered models of care. The collaborative efforts between research institutions, regulatory bodies, and pharmaceutical companies have been instrumental in setting new benchmarks for safety and efficacy standards. Collectively, these transformative shifts have positioned mesalazine as an essential therapeutic agent, ushering in a new era of innovation that promises to enhance the overall quality of care for patients afflicted with chronic inflammatory conditions.

Key Segmentation Insights: Detailed Analysis of Market Divisions

A detailed comprehension of market segmentation reveals the multifaceted nature of the mesalazine market. The analysis is enriched by considering variables across product formulation, routes of administration, application in clinical conditions, end-user preferences, and distribution channels. For instance, product form segmentation encompasses dedicated studies on various forms such as enema solutions, granules, rectal foams, suppositories, and tablets, each of which demonstrates unique advantages based on absorption rates and patient compliance. In parallel, the route of administration is critical as it compares the oral route with the rectal route, identifying disparities in convenience, dosage accuracy, and regional patient preferences.

The application-based segmentation offers further insights, categorizing the market by disease indications including Crohn's disease, inflammatory bowel disease, and ulcerative colitis, each presenting distinct clinical challenges and treatment complexities. Differentiating by end-user highlights the divergence in therapeutic settings, contrasting homecare environments with hospitals and clinics, thus underscoring not only patient management but also the variance in utilization patterns across diverse healthcare infrastructures. Finally, distribution channels are meticulously evaluated by studying the performance of hospital pharmacies, online pharmacies, and retail pharmacies, which collectively contribute to the overall accessibility and market penetration of mesalazine products.

Such segmentation facilitates a granular understanding of market drivers and barriers, enabling stakeholders to align product development strategies with the specific needs of distinct patient groups and healthcare providers. The integrated insights guide investment decisions and product launches that are finely tuned to regional market dynamics, ensuring that therapeutic solutions remain both innovative and accessible.

Based on Product Form, market is studied across Enemas, Granules, Rectal Foam, Suppositories, and Tablets.

Based on Route Of Administration, market is studied across Oral and Rectal.

Based on Application, market is studied across Crohn's Disease, Inflammatory Bowel Disease, and Ulcerative colitis.

Based on End-User, market is studied across Homecare Settings and Hospitals & Clinics.

Based on Distribution Channel, market is studied across Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies.

Key Regional Insights: Geographical Trends and Market Dynamics

Regional analysis reveals distinct trends and opportunities that have a profound impact on the mesalazine market. The Americas continue to be at the forefront of advanced healthcare delivery systems and innovation, setting high benchmarks for clinical practices. Meanwhile, the Europe, Middle East & Africa region shows a balanced mix of mature healthcare setups and emerging economies, driving contributions through robust regulatory frameworks and increasing demand for affordable, effective therapies. The Asia-Pacific region, marked by rapid urbanization and improving healthcare infrastructure, is witnessing substantial growth driven by the expanding middle-class population, increased healthcare spending, and rising awareness about inflammatory conditions.

Understanding these regional variations is vital as each area reflects unique market drivers, regulatory policies, and cultural nuances that shape mesalazine adoption and distribution. Through continuous market monitoring and strategic regional customization, companies can tailor their outreach and product strategies to effectively serve these diverse populations.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Key Companies Insights: Analyzing Market Leaders and Competitive Dynamics

The competitive landscape is characterized by a diverse group of established pharmaceutical companies and emerging players who are redefining market standards through innovation and strategic partnerships. Industry leaders such as AbbVie Inc., Allergan Pharmaceuticals International, Ltd., Amneal Pharmaceuticals, Inc., Apotex Inc., and Axplora Group GmbH have demonstrated robust market performance, complemented by contributions from Cambrex Corporation, Chemi S.p.A., and CordenPharma International. In parallel, companies such as Divi's Laboratories Limited, Dr. Falk Pharma GmbH, Ethypharm SAS, and Ferring Pharmaceuticals have been instrumental in driving technological innovations and clinical trial advancements.

Other significant contributors include Fresenius Kabi, LGM Pharma, Lupin Limited, Pfizer Inc., Rosemont Pharmaceuticals Ltd., Salix Pharmaceuticals, Inc., Sun Pharmaceutical Industries Ltd., and Takeda Pharmaceutical Company Limited. Adding further, Teva Pharmaceuticals, Tillotts Pharma Ltd., Viatris Inc., Zhejiang Hengkang Pharmaceutical Co. Ltd., and Zydus Pharmaceuticals, Inc. are recognized for their commitment to high safety standards and resilient supply chains. Collectively, these companies continue to influence the strategic direction of the mesalazine market, with proactive research and development investments solidifying their market positions as well as driving competitive differentiation through product excellence and customer-centric strategies.

The report delves into recent significant developments in the Mesalazine Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Allergan Pharmaceuticals International, Ltd., Amneal Pharmaceuticals, Inc., Apotex Inc., Axplora Group GmbH, Cambrex Corporation, Chemi S.p.A., CordenPharma International, Divi's Laboratories Limited, Dr. Falk Pharma GmbH, Ethypharm SAS, Ferring Pharmaceuticals, Fresenius Kabi, LGM Pharma, Lupin limited, Pfizer Inc., Rosemont Pharmaceuticals Ltd., Salix Pharmaceuticals, Inc., Sun Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited, Teva Pharmaceuticals, Tillotts Pharma Ltd., Viatris Inc., Zhejiang Hengkang Pharmaceutical Co. Ltd., and Zydus Pharmaceuticals, Inc.. Actionable Recommendations for Industry Leaders: Strategic Moves for Market Leadership

For industry leaders looking to maintain or establish market prominence, the following recommendations provide strategic guidance based on in-depth analysis of current market conditions and future trends. First, companies must prioritize investment in research and development with a focus on the next generation of mesalazine formulations. By leveraging cutting-edge technology and robust clinical evidence, companies can enhance drug efficacy while minimizing adverse effects. Secondly, aligning product launches with regional market dynamics can result in a more effective penetration strategy; tailoring formulations to meet the cultural, economic, and regulatory specifics of various geographies is critical.

Moreover, forging strategic partnerships with key stakeholders in digital health and data analytics can bolster patient support programs and optimize treatment outcomes. Industry leaders should also consider diversifying distribution channels, balancing between traditional hospital pharmacies, innovative online platforms, and trusted retail outlets to ensure widespread accessibility. Finally, engaging in continuous post-market surveillance and real-world evidence studies will provide timely insights into drug performance and patient adherence, allowing for agile adaptations to clinical and market feedback. This proactive approach not only reinforces consumer trust but also positions companies at the forefront of industry innovation.

Conclusion: Strategic Insights and Future Directions in the Mesalazine Market

In conclusion, an expansive evaluation of the mesalazine market reveals an intricate tapestry of opportunities and challenges. The transformative shifts within product development, technology integration, and regional personalization have redefined treatment paradigms and created a dynamic environment ripe for innovation. Detailed segmentation across product forms, administration routes, applications, end-user environments, and distribution channels underscores the complexity of market dynamics and highlights key areas for subsequent focus.

The diverse regional landscape, spanning the Americas, Europe, Middle East & Africa, and Asia-Pacific, has further accentuated the need for tailored strategies that resonate with localized market conditions. Similarly, robust competitive dynamics driven by leading pharmaceutical companies set a high bar for safety, clinical efficacy, and patient-centric care. As the mesalazine market continues to evolve, a careful balance between technological innovation, strategic collaboration, and adaptive market approaches will be essential to sustaining growth and enhancing patient outcomes.

This comprehensive analysis stresses the importance of agility, continuous improvement, and forward-thinking strategies in an increasingly competitive global pharmaceutical market. It is incumbent upon industry stakeholders to adopt a holistic understanding of market trends and to harness these insights for sustained competitive differentiation and operational excellence.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising incidence of inflammatory bowel diseases and ulcerative colitis globally
      • 5.1.1.2. Growing focus on personalized medicine and targeted therapies
      • 5.1.1.3. Increased government funding and supportive policies for the treatment of gastrointestinal disorders
    • 5.1.2. Restraints
      • 5.1.2.1. High manufacturing and production costs driving pricing pressures
    • 5.1.3. Opportunities
      • 5.1.3.1. Strategic collaborations and partnerships in pharmaceutical R&D fostering innovation in mesalazine therapies
      • 5.1.3.2. Innovative clinical trial designs to explore novel mesalazine formulations
    • 5.1.4. Challenges
      • 5.1.4.1. Strict and varying regulatory compliance requirements across different regional markets
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Product Form: Increasing preference for granules due to their ease of administration and flexible dosing
    • 5.2.2. Applications: Expanding application of mesalazine in ulcerative colitis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Mesalazine Market, by Product Form

  • 6.1. Introduction
  • 6.2. Enemas
  • 6.3. Granules
  • 6.4. Rectal Foam
  • 6.5. Suppositories
  • 6.6. Tablets

7. Mesalazine Market, by Route Of Administration

  • 7.1. Introduction
  • 7.2. Oral
  • 7.3. Rectal

8. Mesalazine Market, by Application

  • 8.1. Introduction
  • 8.2. Crohn's Disease
  • 8.3. Inflammatory Bowel Disease
  • 8.4. Ulcerative colitis

9. Mesalazine Market, by End-User

  • 9.1. Introduction
  • 9.2. Homecare Settings
  • 9.3. Hospitals & Clinics

10. Mesalazine Market, by Distribution Channel

  • 10.1. Introduction
  • 10.2. Hospital Pharmacies
  • 10.3. Online Pharmacies
  • 10.4. Retail Pharmacies

11. Americas Mesalazine Market

  • 11.1. Introduction
  • 11.2. Argentina
  • 11.3. Brazil
  • 11.4. Canada
  • 11.5. Mexico
  • 11.6. United States

12. Asia-Pacific Mesalazine Market

  • 12.1. Introduction
  • 12.2. Australia
  • 12.3. China
  • 12.4. India
  • 12.5. Indonesia
  • 12.6. Japan
  • 12.7. Malaysia
  • 12.8. Philippines
  • 12.9. Singapore
  • 12.10. South Korea
  • 12.11. Taiwan
  • 12.12. Thailand
  • 12.13. Vietnam

13. Europe, Middle East & Africa Mesalazine Market

  • 13.1. Introduction
  • 13.2. Denmark
  • 13.3. Egypt
  • 13.4. Finland
  • 13.5. France
  • 13.6. Germany
  • 13.7. Israel
  • 13.8. Italy
  • 13.9. Netherlands
  • 13.10. Nigeria
  • 13.11. Norway
  • 13.12. Poland
  • 13.13. Qatar
  • 13.14. Russia
  • 13.15. Saudi Arabia
  • 13.16. South Africa
  • 13.17. Spain
  • 13.18. Sweden
  • 13.19. Switzerland
  • 13.20. Turkey
  • 13.21. United Arab Emirates
  • 13.22. United Kingdom

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2024
  • 14.2. FPNV Positioning Matrix, 2024
  • 14.3. Competitive Scenario Analysis
    • 14.3.1. Amneal strengthens its market footprint with the dual launch of mesalamine for inflammatory bowel disease
    • 14.3.2. Ethypharm expands its mesalazine portfolio in China
    • 14.3.3. Takeda's FDA approval of subcutaneous ENTYVIO signals a strategic transition from IV induction to patient-friendly
  • 14.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AbbVie Inc.
  • 2. Allergan Pharmaceuticals International, Ltd.
  • 3. Amneal Pharmaceuticals, Inc.
  • 4. Apotex Inc.
  • 5. Axplora Group GmbH
  • 6. Cambrex Corporation
  • 7. Chemi S.p.A.
  • 8. CordenPharma International
  • 9. Divi's Laboratories Limited
  • 10. Dr. Falk Pharma GmbH
  • 11. Ethypharm SAS
  • 12. Ferring Pharmaceuticals
  • 13. Fresenius Kabi
  • 14. LGM Pharma
  • 15. Lupin limited
  • 16. Pfizer Inc.
  • 17. Rosemont Pharmaceuticals Ltd.
  • 18. Salix Pharmaceuticals, Inc.
  • 19. Sun Pharmaceutical Industries Ltd.
  • 20. Takeda Pharmaceutical Company Limited
  • 21. Teva Pharmaceuticals
  • 22. Tillotts Pharma Ltd.
  • 23. Viatris Inc.
  • 24. Zhejiang Hengkang Pharmaceutical Co. Ltd.
  • 25. Zydus Pharmaceuticals, Inc.

LIST OF FIGURES

  • FIGURE 1. MESALAZINE MARKET MULTI-CURRENCY
  • FIGURE 2. MESALAZINE MARKET MULTI-LANGUAGE
  • FIGURE 3. MESALAZINE MARKET RESEARCH PROCESS
  • FIGURE 4. MESALAZINE MARKET SIZE, 2024 VS 2030
  • FIGURE 5. GLOBAL MESALAZINE MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 6. GLOBAL MESALAZINE MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 7. GLOBAL MESALAZINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL MESALAZINE MARKET SIZE, BY PRODUCT FORM, 2024 VS 2030 (%)
  • FIGURE 9. GLOBAL MESALAZINE MARKET SIZE, BY PRODUCT FORM, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL MESALAZINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
  • FIGURE 11. GLOBAL MESALAZINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL MESALAZINE MARKET SIZE, BY APPLICATION, 2024 VS 2030 (%)
  • FIGURE 13. GLOBAL MESALAZINE MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL MESALAZINE MARKET SIZE, BY END-USER, 2024 VS 2030 (%)
  • FIGURE 15. GLOBAL MESALAZINE MARKET SIZE, BY END-USER, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 16. GLOBAL MESALAZINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
  • FIGURE 17. GLOBAL MESALAZINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 18. AMERICAS MESALAZINE MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 19. AMERICAS MESALAZINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 20. UNITED STATES MESALAZINE MARKET SIZE, BY STATE, 2024 VS 2030 (%)
  • FIGURE 21. UNITED STATES MESALAZINE MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 22. ASIA-PACIFIC MESALAZINE MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 23. ASIA-PACIFIC MESALAZINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 24. EUROPE, MIDDLE EAST & AFRICA MESALAZINE MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 25. EUROPE, MIDDLE EAST & AFRICA MESALAZINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 26. MESALAZINE MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 27. MESALAZINE MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. MESALAZINE MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL MESALAZINE MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL MESALAZINE MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL MESALAZINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. MESALAZINE MARKET DYNAMICS
  • TABLE 7. GLOBAL MESALAZINE MARKET SIZE, BY PRODUCT FORM, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL MESALAZINE MARKET SIZE, BY ENEMAS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL MESALAZINE MARKET SIZE, BY GRANULES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL MESALAZINE MARKET SIZE, BY RECTAL FOAM, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL MESALAZINE MARKET SIZE, BY SUPPOSITORIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL MESALAZINE MARKET SIZE, BY TABLETS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL MESALAZINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL MESALAZINE MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL MESALAZINE MARKET SIZE, BY RECTAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL MESALAZINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL MESALAZINE MARKET SIZE, BY CROHN'S DISEASE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL MESALAZINE MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL MESALAZINE MARKET SIZE, BY ULCERATIVE COLITIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL MESALAZINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL MESALAZINE MARKET SIZE, BY HOMECARE SETTINGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL MESALAZINE MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL MESALAZINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL MESALAZINE MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL MESALAZINE MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL MESALAZINE MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. AMERICAS MESALAZINE MARKET SIZE, BY PRODUCT FORM, 2018-2030 (USD MILLION)
  • TABLE 28. AMERICAS MESALAZINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 29. AMERICAS MESALAZINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 30. AMERICAS MESALAZINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 31. AMERICAS MESALAZINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 32. AMERICAS MESALAZINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 33. ARGENTINA MESALAZINE MARKET SIZE, BY PRODUCT FORM, 2018-2030 (USD MILLION)
  • TABLE 34. ARGENTINA MESALAZINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 35. ARGENTINA MESALAZINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 36. ARGENTINA MESALAZINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 37. ARGENTINA MESALAZINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 38. BRAZIL MESALAZINE MARKET SIZE, BY PRODUCT FORM, 2018-2030 (USD MILLION)
  • TABLE 39. BRAZIL MESALAZINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 40. BRAZIL MESALAZINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 41. BRAZIL MESALAZINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 42. BRAZIL MESALAZINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 43. CANADA MESALAZINE MARKET SIZE, BY PRODUCT FORM, 2018-2030 (USD MILLION)
  • TABLE 44. CANADA MESALAZINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 45. CANADA MESALAZINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 46. CANADA MESALAZINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 47. CANADA MESALAZINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 48. MEXICO MESALAZINE MARKET SIZE, BY PRODUCT FORM, 2018-2030 (USD MILLION)
  • TABLE 49. MEXICO MESALAZINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 50. MEXICO MESALAZINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 51. MEXICO MESALAZINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 52. MEXICO MESALAZINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 53. UNITED STATES MESALAZINE MARKET SIZE, BY PRODUCT FORM, 2018-2030 (USD MILLION)
  • TABLE 54. UNITED STATES MESALAZINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 55. UNITED STATES MESALAZINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 56. UNITED STATES MESALAZINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 57. UNITED STATES MESALAZINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 58. UNITED STATES MESALAZINE MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 59. ASIA-PACIFIC MESALAZINE MARKET SIZE, BY PRODUCT FORM, 2018-2030 (USD MILLION)
  • TABLE 60. ASIA-PACIFIC MESALAZINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 61. ASIA-PACIFIC MESALAZINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 62. ASIA-PACIFIC MESALAZINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 63. ASIA-PACIFIC MESALAZINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 64. ASIA-PACIFIC MESALAZINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 65. AUSTRALIA MESALAZINE MARKET SIZE, BY PRODUCT FORM, 2018-2030 (USD MILLION)
  • TABLE 66. AUSTRALIA MESALAZINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 67. AUSTRALIA MESALAZINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 68. AUSTRALIA MESALAZINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 69. AUSTRALIA MESALAZINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 70. CHINA MESALAZINE MARKET SIZE, BY PRODUCT FORM, 2018-2030 (USD MILLION)
  • TABLE 71. CHINA MESALAZINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 72. CHINA MESALAZINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 73. CHINA MESALAZINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 74. CHINA MESALAZINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 75. INDIA MESALAZINE MARKET SIZE, BY PRODUCT FORM, 2018-2030 (USD MILLION)
  • TABLE 76. INDIA MESALAZINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 77. INDIA MESALAZINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 78. INDIA MESALAZINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 79. INDIA MESALAZINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 80. INDONESIA MESALAZINE MARKET SIZE, BY PRODUCT FORM, 2018-2030 (USD MILLION)
  • TABLE 81. INDONESIA MESALAZINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 82. INDONESIA MESALAZINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 83. INDONESIA MESALAZINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 84. INDONESIA MESALAZINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 85. JAPAN MESALAZINE MARKET SIZE, BY PRODUCT FORM, 2018-2030 (USD MILLION)
  • TABLE 86. JAPAN MESALAZINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 87. JAPAN MESALAZINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 88. JAPAN MESALAZINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 89. JAPAN MESALAZINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 90. MALAYSIA MESALAZINE MARKET SIZE, BY PRODUCT FORM, 2018-2030 (USD MILLION)
  • TABLE 91. MALAYSIA MESALAZINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 92. MALAYSIA MESALAZINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 93. MALAYSIA MESALAZINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 94. MALAYSIA MESALAZINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 95. PHILIPPINES MESALAZINE MARKET SIZE, BY PRODUCT FORM, 2018-2030 (USD MILLION)
  • TABLE 96. PHILIPPINES MESALAZINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 97. PHILIPPINES MESALAZINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 98. PHILIPPINES MESALAZINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 99. PHILIPPINES MESALAZINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 100. SINGAPORE MESALAZINE MARKET SIZE, BY PRODUCT FORM, 2018-2030 (USD MILLION)
  • TABLE 101. SINGAPORE MESALAZINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 102. SINGAPORE MESALAZINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 103. SINGAPORE MESALAZINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 104. SINGAPORE MESALAZINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 105. SOUTH KOREA MESALAZINE MARKET SIZE, BY PRODUCT FORM, 2018-2030 (USD MILLION)
  • TABLE 106. SOUTH KOREA MESALAZINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 107. SOUTH KOREA MESALAZINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 108. SOUTH KOREA MESALAZINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 109. SOUTH KOREA MESALAZINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 110. TAIWAN MESALAZINE MARKET SIZE, BY PRODUCT FORM, 2018-2030 (USD MILLION)
  • TABLE 111. TAIWAN MESALAZINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 112. TAIWAN MESALAZINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 113. TAIWAN MESALAZINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 114. TAIWAN MESALAZINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 115. THAILAND MESALAZINE MARKET SIZE, BY PRODUCT FORM, 2018-2030 (USD MILLION)
  • TABLE 116. THAILAND MESALAZINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 117. THAILAND MESALAZINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 118. THAILAND MESALAZINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 119. THAILAND MESALAZINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 120. VIETNAM MESALAZINE MARKET SIZE, BY PRODUCT FORM, 2018-2030 (USD MILLION)
  • TABLE 121. VIETNAM MESALAZINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 122. VIETNAM MESALAZINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 123. VIETNAM MESALAZINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 124. VIETNAM MESALAZINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 125. EUROPE, MIDDLE EAST & AFRICA MESALAZINE MARKET SIZE, BY PRODUCT FORM, 2018-2030 (USD MILLION)
  • TABLE 126. EUROPE, MIDDLE EAST & AFRICA MESALAZINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 127. EUROPE, MIDDLE EAST & AFRICA MESALAZINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 128. EUROPE, MIDDLE EAST & AFRICA MESALAZINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 129. EUROPE, MIDDLE EAST & AFRICA MESALAZINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 130. EUROPE, MIDDLE EAST & AFRICA MESALAZINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 131. DENMARK MESALAZINE MARKET SIZE, BY PRODUCT FORM, 2018-2030 (USD MILLION)
  • TABLE 132. DENMARK MESALAZINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 133. DENMARK MESALAZINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 134. DENMARK MESALAZINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 135. DENMARK MESALAZINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 136. EGYPT MESALAZINE MARKET SIZE, BY PRODUCT FORM, 2018-2030 (USD MILLION)
  • TABLE 137. EGYPT MESALAZINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 138. EGYPT MESALAZINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 139. EGYPT MESALAZINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 140. EGYPT MESALAZINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 141. FINLAND MESALAZINE MARKET SIZE, BY PRODUCT FORM, 2018-2030 (USD MILLION)
  • TABLE 142. FINLAND MESALAZINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 143. FINLAND MESALAZINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 144. FINLAND MESALAZINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 145. FINLAND MESALAZINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 146. FRANCE MESALAZINE MARKET SIZE, BY PRODUCT FORM, 2018-2030 (USD MILLION)
  • TABLE 147. FRANCE MESALAZINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 148. FRANCE MESALAZINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 149. FRANCE MESALAZINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 150. FRANCE MESALAZINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 151. GERMANY MESALAZINE MARKET SIZE, BY PRODUCT FORM, 2018-2030 (USD MILLION)
  • TABLE 152. GERMANY MESALAZINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 153. GERMANY MESALAZINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 154. GERMANY MESALAZINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 155. GERMANY MESALAZINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 156. ISRAEL MESALAZINE MARKET SIZE, BY PRODUCT FORM, 2018-2030 (USD MILLION)
  • TABLE 157. ISRAEL MESALAZINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 158. ISRAEL MESALAZINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 159. ISRAEL MESALAZINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 160. ISRAEL MESALAZINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 161. ITALY MESALAZINE MARKET SIZE, BY PRODUCT FORM, 2018-2030 (USD MILLION)
  • TABLE 162. ITALY MESALAZINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 163. ITALY MESALAZINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 164. ITALY MESALAZINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 165. ITALY MESALAZINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 166. NETHERLANDS MESALAZINE MARKET SIZE, BY PRODUCT FORM, 2018-2030 (USD MILLION)
  • TABLE 167. NETHERLANDS MESALAZINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 168. NETHERLANDS MESALAZINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 169. NETHERLANDS MESALAZINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 170. NETHERLANDS MESALAZINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 171. NIGERIA MESALAZINE MARKET SIZE, BY PRODUCT FORM, 2018-2030 (USD MILLION)
  • TABLE 172. NIGERIA MESALAZINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 173. NIGERIA MESALAZINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 174. NIGERIA MESALAZINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 175. NIGERIA MESALAZINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 176. NORWAY MESALAZINE MARKET SIZE, BY PRODUCT FORM, 2018-2030 (USD MILLION)
  • TABLE 177. NORWAY MESALAZINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 178. NORWAY MESALAZINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 179. NORWAY MESALAZINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 180. NORWAY MESALAZINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 181. POLAND MESALAZINE MARKET SIZE, BY PRODUCT FORM, 2018-2030 (USD MILLION)
  • TABLE 182. POLAND MESALAZINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 183. POLAND MESALAZINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 184. POLAND MESALAZINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 185. POLAND MESALAZINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 186. QATAR MESALAZINE MARKET SIZE, BY PRODUCT FORM, 2018-2030 (USD MILLION)
  • TABLE 187. QATAR MESALAZINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 188. QATAR MESALAZINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 189. QATAR MESALAZINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 190. QATAR MESALAZINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 191. RUSSIA MESALAZINE MARKET SIZE, BY PRODUCT FORM, 2018-2030 (USD MILLION)
  • TABLE 192. RUSSIA MESALAZINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 193. RUSSIA MESALAZINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 194. RUSSIA MESALAZINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 195. RUSSIA MESALAZINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 196. SAUDI ARABIA MESALAZINE MARKET SIZE, BY PRODUCT FORM, 2018-2030 (USD MILLION)
  • TABLE 197. SAUDI ARABIA MESALAZINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 198. SAUDI ARABIA MESALAZINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 199. SAUDI ARABIA MESALAZINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 200. SAUDI ARABIA MESALAZINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 201. SOUTH AFRICA MESALAZINE MARKET SIZE, BY PRODUCT FORM, 2018-2030 (USD MILLION)
  • TABLE 202. SOUTH AFRICA MESALAZINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 203. SOUTH AFRICA MESALAZINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 204. SOUTH AFRICA MESALAZINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 205. SOUTH AFRICA MESALAZINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 206. SPAIN MESALAZINE MARKET SIZE, BY PRODUCT FORM, 2018-2030 (USD MILLION)
  • TABLE 207. SPAIN MESALAZINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 208. SPAIN MESALAZINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 209. SPAIN MESALAZINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 210. SPAIN MESALAZINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 211. SWEDEN MESALAZINE MARKET SIZE, BY PRODUCT FORM, 2018-2030 (USD MILLION)
  • TABLE 212. SWEDEN MESALAZINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 213. SWEDEN MESALAZINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 214. SWEDEN MESALAZINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 215. SWEDEN MESALAZINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 216. SWITZERLAND MESALAZINE MARKET SIZE, BY PRODUCT FORM, 2018-2030 (USD MILLION)
  • TABLE 217. SWITZERLAND MESALAZINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 218. SWITZERLAND MESALAZINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 219. SWITZERLAND MESALAZINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 220. SWITZERLAND MESALAZINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 221. TURKEY MESALAZINE MARKET SIZE, BY PRODUCT FORM, 2018-2030 (USD MILLION)
  • TABLE 222. TURKEY MESALAZINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 223. TURKEY MESALAZINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 224. TURKEY MESALAZINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 225. TURKEY MESALAZINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 226. UNITED ARAB EMIRATES MESALAZINE MARKET SIZE, BY PRODUCT FORM, 2018-2030 (USD MILLION)
  • TABLE 227. UNITED ARAB EMIRATES MESALAZINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 228. UNITED ARAB EMIRATES MESALAZINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 229. UNITED ARAB EMIRATES MESALAZINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 230. UNITED ARAB EMIRATES MESALAZINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 231. UNITED KINGDOM MESALAZINE MARKET SIZE, BY PRODUCT FORM, 2018-2030 (USD MILLION)
  • TABLE 232. UNITED KINGDOM MESALAZINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 233. UNITED KINGDOM MESALAZINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 234. UNITED KINGDOM MESALAZINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 235. UNITED KINGDOM MESALAZINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 236. MESALAZINE MARKET SHARE, BY KEY PLAYER, 2024
  • TABLE 237. MESALAZINE MARKET, FPNV POSITIONING MATRIX, 2024